In short
This article discusses a clinical trial investigating the use of Doxapram Hydrochloride Monohydrate in treating apnea of prematurity. The study aims to determine the safety and effectiveness of this drug compared to a placebo in reducing death and neurodevelopmental impairment in preterm newborns. This Phase III trial involves multiple centers and focuses on infants born before 29 weeks of gestation.
At a glance
- Drug Name
- Doxapram Hydrochloride Monohydrate
- Trial Phase
- Phase III
- Medical Condition
- Apnea of prematurity
- Main Objective
- Investigate safety and effectiveness in reducing death and neurodevelopmental impairment
- Participant Age
- Preterm newborns (< 29 weeks gestational age)
- Administration Method
- Intravenous infusion
- Maximum Daily Dose
- 48 mg/kg
- Treatment Duration
- Up to 10 days
- Primary Outcome Measure
- Death or severe disability at 18-24 months corrected age
What is Doxapram?
Doxapram Hydrochloride Monohydrate, also known simply as Doxapram, is a medication currently being studied for its potential use in treating breathing problems in premature babies. It belongs to a class of drugs called respiratory stimulants, which means it helps to encourage breathing.
Medical Condition: Apnea of Prematurity
The main medical condition that Doxapram is being studied for is called apnea of prematurity. This is a common problem in premature babies where they temporarily stop breathing for short periods. These pauses in breathing can be frequent or severe and may require medical intervention.
Current Clinical Trial
A large-scale clinical trial is currently underway to investigate the safety and effectiveness of Doxapram in treating apnea of prematurity. This trial is known as a Phase III clinical trial, which means it's in an advanced stage of testing. The study is described as an "international double-blinded multicenter randomized controlled trial". Let's break down what this means:
- International: The study is being conducted in multiple countries.
- Double-blinded: Neither the patients (in this case, the babies' parents) nor the doctors know who is receiving the real drug and who is receiving a placebo (a harmless substance with no medical effect).
- Multicenter: The study is taking place at multiple hospitals or medical centers.
- Randomized controlled: Participants are randomly assigned to either receive Doxapram or a placebo, which helps ensure the results are not biased.
The main goal of this trial is to see if Doxapram is safe and effective in reducing deaths and neurodevelopmental problems (issues with brain and nervous system development) in premature babies at 18 to 24 months of corrected age, compared to a placebo.
Eligibility Criteria
The trial has specific criteria for which babies can participate. Some key inclusion criteria are:
- Babies born before 29 weeks of pregnancy
- At least 5 days old
- Already receiving caffeine therapy (another treatment for apnea of prematurity)
- Experiencing frequent or severe apneas that require medical intervention
Some reasons a baby might not be eligible include:
- Previous use of Doxapram
- Certain genetic conditions or major birth defects
- Being in palliative care (end-of-life care)
Drug Information
In this trial, Doxapram is being given as a solution for infusion, which means it's administered directly into the bloodstream through a vein (intravenously). The maximum daily dose being tested is 48 mg per kilogram of body weight, with a maximum rate of 2 mg per kilogram per hour. The treatment period can last up to 10 days.
Potential Benefits and Risks
While the full results of this study are not yet known, the researchers hope that Doxapram might help reduce the risk of death and severe disability in premature babies with apnea. However, as with any medical treatment, there may be risks involved. The purpose of this clinical trial is to better understand both the potential benefits and any possible risks of using Doxapram in premature babies.
It's important to note that this medication is still being studied and is not yet approved for general use in treating apnea of prematurity. The results of this trial will help doctors and researchers determine if Doxapram should be used more widely for this condition.